Virtual Library

Start Your Search

Victor HF de Jesus



Author of

  • +

    P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.15-07 - Geriatric Oncology - Lung Cancer in Elderly Patients and Palliative Treatment: Prospective Analysis of A. C. Camargo Cancer Center (ID 13550)

      16:45 - 18:00  |  Author(s): Victor HF de Jesus

      • Abstract
      • Slides

      Background

      Special attention is required by elderly population, due to chemotherapy (ch) risks and comorbidities, which may limit the capacity to deliver optimal cancer care. We aimed to describe the clinical features and survival outcomes of elderly patients (pts) with lung adenocarcinoma (ADC) treated with non-curative intent at A. C. Camargo Cancer Center.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We evaluated all pts aged 70+ with lung ADC treated with ch or target therapy in 1st or 2nd-line from 2007 to 2015 who underwent a comprehensive geriatric assessment (CGA), in a convenient prospective series. We used summary statistics to describe the population. Overall survival (OS) was calculated according to Kaplan-Meier method, from CGA date to last follow-up or death. We performed univariate and multivariate analysis in order to look for potential prognostic factors for OS.

      4c3880bb027f159e801041b1021e88e8 Result

      CGA was done in 55 pts aged ≥70y with lung ADC. The median age was 76y and 22% had ECOG ≥ 2. Half of pts were male. 51% had polypharmacy (≥5 drugs). Pts were functionally classified according to activities of daily living (ADL): 76% as Katz A and 50% as Lawton ≤27. 68.5% were at risk for malnutrition or malnourished. The median age-adjusted Charlson Comorbidity score was 10 – remembering that 4+ is considered clinically significant. 61% had ≥2 comorbidities and 26 pts had at least 2 metastatic sites. CNS was affected in 7.5% of the cases and liver in 9.2%. 79.6% of the pts underwent ch and the others received target therapy. After follow-up of 29m, median OS was 17.1 months (13.5-27.8m). In univariate analysis, significantly worse survival outcomes were observed for pts with ECOG 2-4 (HR 10.6; p < 0.001), increasing number of sites of metastases (HR 2.2; p = 0.04) and hepatic metastasis (HR 6.03; p < 0.001). In the multivariate analysis, male gender, ECOG 2-4 and liver metastasis were associated with higher risk of death.

      8eea62084ca7e541d918e823422bd82e Conclusion

      ADL, an important part of CGA, showed little prognostic value in our small population. Pts with ECOG 2-4 or hepatic metastasis were those that presented the highest risk of death. CGA is a good tool to help in stratifying risk of elderly cancer pts and is mandatory in cost-benefit analysis to identify the best treatment to each individual patient.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.